Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBG002 in Relapsed/Refractory Multiple Myeloma
NCT06705725Phase 1Not yet recruiting
- Sponsor
- Zhejiang Carbiogene Therapeutics Co. Ltd
- Start
- Dec 2024
- Primary completion
- Oct 2027
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CBG002 in multiple myeloma (MM), sponsored by Zhejiang Carbiogene Therapeutics Co. Ltd. Primary endpoints: Adverse Events and Dose Limiting Toxicity. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
CBG002
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06705725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705725.